Percutaneous intratumoral injection of cisplatin microspheres in tumor-bearing rats to diminish acute nephrotoxicity.
Poly(D,L-lactide) microspheres loaded with cisplatin (PLA-CDDP MS) were prepared by a solvent evaporation technique for direct intratumoral injection. The microspheres, 50-100 microns, containing 40.04% of cisplatin produce sustained release in vitro. PLA-CDDP MS (6 mg/kg body weight of cisplatin) suspensions were injected intratumorally into mammary tumors in rats. Cisplatin solution (6 mg/kg body weight) was injected either intratumorally or intraperitoneally in two groups. After treatments, the tumor size decreased in each of the groups as a function of time. Sixteen days post-injection, the tumors had either disappeared or significantly shrunk. PLA-CDDP MS had a similar antitumor effect compared with cisplatin aqueous solution. Blood urea nitrogen, serum creatinine and histopathology examinations revealed that the renal toxicity in the PLA-CDDP MS group was significantly less than in the control groups. These results indicate that intratumoral injection of PLA-CDDP MS maintains anticancer potency and reduces acute renal toxicity.
Kuang
L
L
Division of Diagnostic Imaging, University of Texas MD Anderson Center, Houston 77030, USA.
Yang
D J
DJ
Inoue
T
T
Liu
W C
WC
Wallace
S
S
Wright
K C
KC
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D004337:Drug Carriers; D004341:Drug Evaluation; D015552:Injections, Intralesional; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D008863:Microspheres; D051381:Rats
D000970:Antineoplastic Agents; D004337:Drug Carriers; D002945:Cisplatin